1 |
Maiso P, Huynh D, Moschetta M, et al. Metabolic signature identifies novel targets for drug resistance in multiple myeloma. Cancer Res 2015; 75:2071-82.
|
2 |
Röllig C, Knop S, Bornhäuser M. Multiple myeloma. Lancet 2015; 385:2197-208.
|
3 |
Mehta GR, Suhail F, Haddad RY. Multiple myeloma. Dis Mon 2014; 60:483-8.
|
4 |
Qu YJ, Liu TW. The progress of multiple myeloma treat- ment. J Pract Oncol 2013; 4:351-5.
|
5 |
Dass K, Ahmad A, Azmi AS, et al. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 2008; 34:122-36.
|
6 |
Jacobsen B, Ploug M. The urokinase receptor and its structural homologue C4.4A in human cancer: expression, prognosis and pharmacological inhibition. Curr Med Chem 2008; 15:2559-73.
|
7 |
Duffy MJ, O’Grady P, Devaney D, et al. Urokinase- plasminogen activator, a marker for aggressive breast carcinomas preliminary report. Cancer 1988; 18:531-6.
|
8 |
Vassalli JD, Baccino D, Belin D. A cellular binding site for the Mr 55 000 form of the human plasminogen activator, urokinase. J Cell Biol 1985; 100:86-92.
|
9 |
Béné MC, Castoldi G, Knapp W, et al. CD87 (urokinase- type plasminogen activator receptor), function and pathology in hematological disorders: a review. Leukemia 2004; 18:394-400.
|
10 |
Luo LH, Xu GB, Lu XG. Detection and clinical significance of plasma urokinase-type lasminogen activator and its soluble receptor in patients with multiple myeloma. Zhejiang Da Xue Xue Bao Yi Xue Ban 2003; 32:529-32.
|
11 |
Roodman GD. Role of the bone marrow microen- vironment in multiple myeloma. J Bone Miner Res 2002; 17:1921-5.
|
12 |
Zhang ZN, Shen T. Standard diagnosis and curative effect of hematologic disease. 2nd ed. Beijing: Science Press, 1998.
|
13 |
Bataille R, Jourdan M, Zhang XG, et al. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989; 84:2008-11.
|
14 |
Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010; 11:23-36.
|
15 |
Ferraris GM, Sidenius N. Urokinase plasminogen activator receptor: a functional integrator of extracellular proteoly- sis, cell adhesion, and signal transduction. Semin Thromb Hemost 2013; 39:347-55.
|
16 |
Magnussen S, Hadler-Olsen E, Latysheva N. Tumour microenvironments induce expression of urokinase plasminogen activator receptor (uPAR) and concomitant activation of gelatinolytic enzymes. PLoS One 2014; 9:e105929.
|
17 |
Zhuang T, Chelluboina B, Ponnala S, et al. Involvement of nitric oxide synthase in matrix metalloproteinase-9 and/ or urokinase plasminogen activator receptor-mediated glioma cell migration. BMC Cancer 2013; 13:590.
|
18 |
Almasi CE, Drivsholm L, Pappot H, et al. The liberated domain I of urokinase plasminogen activator receptor—a new tumour marker in small cell lung cancer. APMIS 2013; 121:189-96.
|
19 |
Ahn SB, Chan C, Dent OF, et al. Epithelial and stromal cell urokinase plasminogen activator receptor expression diff- erentially correlates with survival in rectal cancer stages B and C patients. PLoS One 2015; 10:e0117786.
|
20 |
Li Y, Sun B, Zhao X, et al. Subpopulations of uPAR (+) contribute to vasculogenic mimicry and metastasis in large cell lung cancer. Exp Mol Pathol 2015; 98:136-44.
|
21 |
Dohn LH, Illemann M, Høyer-Hansen G, et al. Urokinase- type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial car- cinoma of the bladder. Urol Oncol 2015; 33:165.e15-24.
|
22 |
Magnussen S, Rikardsen OG, Hadler-Olsen E, et al. Urokinase plasminogen activator receptor (uPAR) and plasminogenactivator inhibitor-1 (PAI-1) are potential predictive biomarkers in early stage oral squamous cell carcinomas (OSCC). PLoS One 2014; 9:e101895.
|
23 |
Hou J, Li X, Li C, et al. Plasma membrane gp96 enhances invasion and metastatic potential of liver cancer via regulation of uPAR. Mol Oncol 2015; 9:1312-23.
|
24 |
Laurenzana A, Biagioni A, Bianchini F, et al. Inhibition of uPAR-TGFβ crosstalk blocks MSC-dependent EMT in melanoma cells. J Mol Med 2015; 93:783-94.
|
25 |
Hjertner O, Qvigstad G, Hjorth-Hansen H, et al. Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells. Br J Haematol 2000; 109:815-22.
|